carbapenems has been researched along with azomycin in 3 studies
Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (azomycin) | Trials (azomycin) | Recent Studies (post-2010) (azomycin) |
---|---|---|---|---|---|
7,355 | 147 | 5,277 | 4,790 | 418 | 1,580 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Suppola, JP; Vaara, M; Valtonen, VV; Volin, L | 1 |
Nuermberger, EL; Spigelman, MK; Yew, WW | 1 |
Caminero, JA; Scardigli, A | 1 |
1 review(s) available for carbapenems and azomycin
Article | Year |
---|---|
Current development and future prospects in chemotherapy of tuberculosis.
Topics: Adamantane; Animals; Antitubercular Agents; Carbapenems; Clinical Trials as Topic; Diarylquinolines; Drug Delivery Systems; Ethylenediamines; Fluoroquinolones; Humans; Isonicotinic Acids; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Patient Compliance; Pyrroles; Quinolines; Rifamycins; Tuberculosis, Pulmonary | 2010 |
2 other study(ies) available for carbapenems and azomycin
Article | Year |
---|---|
Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies.
Topics: Aminoglycosides; Ampicillin Resistance; Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Cephalosporins; Colony Count, Microbial; Drug Resistance, Microbial; Enterococcus; Enterococcus faecium; Feces; Hematologic Neoplasms; Humans; Microbial Sensitivity Tests; Nitroimidazoles; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin | 1996 |
Classification of antituberculosis drugs: a new proposal based on the most recent evidence.
Topics: Antitubercular Agents; Carbapenems; Clavulanic Acid; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Infectious Disease Medicine; Linezolid; Nitroimidazoles; Oxazoles; Practice Guidelines as Topic; Tuberculosis, Multidrug-Resistant; World Health Organization | 2015 |